Clinical trials: Antipsychotic Agents
Schizophrenia, Bipolar Disorder
Effectiveness of Anti-Psychotic in GPs Setting
Evaluating the effectiveness of atypical antipsychotics in the community - a prospective, multicentre, observational study to evaluate the impact on Quality of Life of GP-based management of antipsychotic treatment in Belgium
- Trial name
- Serenity (NCT00543088)
- Where
- 57 sites in Belgium
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Schizophrenia
A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the pharmacokinetics, safety and efficacy of MP-214 in patients with schizophrenia.
- Trial name
- NCT01626859
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- Japan
- Volunteers
- 38 people
- Sponsor
- Tanabe Pharma Corporation
Psychotic Disorders, Bipolar Disorder
Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI
The purpose of this study is to compare abdominal weight gain and fat distribution in people taking aripiprazole versus risperidone or quetiapine, to people not taking any of these antipsychotic medications.
- Conditions
- Psychotic Disorders, Bipolar Disorder, Metabolic Syndrome X
- Trial name
- CALM (NCT01739127)
- Testing
- Aripiprazole, Risperidone/Quetiapine
- Where
- Canada
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Schizophrenia Spectrum, Schizophrenia
The Safety and Effectiveness of dTMS for Reducing Antipsychotic-induced Weight Gain
Antipsychotic-induced metabolic disturbances, especially weight gain, are common in patients with schizophrenia. There are no hitherto effective treatments for reducing antipsychotic-induced weight gain.
- Conditions
- Schizophrenia Spectrum, Schizophrenia, Antipsychotic Induced Weight Gain
- Trial name
- dTMS (NCT07795554)
- Testing
- dTMS of accelerated intermittent theta burst stimulation, ACC-iTBS
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Xiangya Hospital of Central South University
Diabetes
Metabolic Effects of Antipsychotic Substitution in Children
This project aims to identify whether therapeutic substitution of aripiprazole for risperidone or olanzapine, combined with standard nutrition intervention, will impact the metabolic changes associated with antipsychotic…
- Trial name
- SMEAC (NCT00910780)
- Testing
- Aripiprazole, Zyprexa, Risperdal
- Sponsor
- Washington University School of Medicine
Pregnancy, Mental Disorders
The National Register of Antipsychotic Medication in Pregnancy (NRAMP)
The National Register of Antipsychotic Medication in Pregnancy (NRAMP)is an observational, nationwide study involving women of child-bearing age who take antipsychotic medication during pregnancy.
- Trial name
- NRAMP (NCT00686946)
- Where
- Australia
- Volunteers
- 500 people
- Sponsor
- The Alfred
Healthy
The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals
The primary aim of this study is to investigate antipsychotic drug effects on healthy brain metabolism.
- Trial name
- NCT02536846
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Dost Ongur
Schizophrenia
Safety and Efficacy of Cariprazine in Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.
- Trial name
- NCT01104779
- Testing
- Cariprazine
- Where
- 41 sites in United States, Colombia and 2 more
- Volunteers
- 446 people
- Sponsor
- Forest Laboratories
Psychosis, Remission
Guided Dose Reduction of Antipsychotic in Patients With Psychosis in Remitted States
A 2-year prospective observational study comparing a group of patients in remitted states of psychosis undergoing guided antipsychotic dose reduction to a similar group of patients under maintenance antipsychotic treatment with…
- Trial name
- GDR (NCT03248180)
- Where
- Taiwan
- Volunteers
- 160 people
- Sponsor
- National Taiwan University Hospital
Schizophrenia; Psychosis, Schizo Affective Disorder
Adapted Physical Activity Program for Patients Undergoing Antipsychotic Treatment of a First Episode of Psychosis
The purpose of this PILOT feasibility study is to verify the acceptability, feasibility, and compliance to the DYNAMO-PSY program among young adults treated with antipsychotics for a first episode of psychosis (FEP).
- Conditions
- Schizophrenia; Psychosis, Schizo Affective Disorder, First Episode Psychosis (FEP)
- Trial name
- DYNAMO-PSY (NCT06643871)
- Testing
- Adapted physical activity program involving connected bikes
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier St Anne
Bipolar Disorder
Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder
The purpose of this study is to learn more about weight gain and related side effects when children are treated with antipsychotic medicine for mood disorders.
- Trial name
- PAMS (NCT00746252)
- Testing
- risperidone, aripiprazole
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Maryland, Baltimore
Colon Cancer Stage III
Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer
chlorpromazine displays a series of remarkable bio-molecular effects in cancer cells, as inhibition of cell growth, nuclear aberrations, inhibition of the phosphoinositide 3-kinase/mammilian target of rapamycin (PI3K/mTOR) axis…
- Trial name
- NCT05433402
- Testing
- ChlorproMAZINE 50 MG, Control
- Where
- Egypt
- Sponsor
- Sadat City University
Schizophrenia
Safety and Efficacy of Zicronapine in Patients With Schizophrenia
To assess the effect of zicronapine versus risperidone on metabolic parameters comprising body weight, body mass index (BMI), waist circumference, levels of fasting blood lipids and glucose during 6 months of treatment.
- Trial name
- NCT01295372
- Testing
- Zicronapine, Risperidone
- Where
- 24 sites in Czechia, Estonia and 3 more
- Volunteers
- 160 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Schizoaffective
The Consta Club: A Demonstration Project for Setting up a Consta Club in a Community Mental Health Center
This study will establish a bi-weekly Consta Club. Participants will begin taking Risperdal Consta after being recommended by their treating physician.
- Trial name
- NCT00845572
- Testing
- Consta Club
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia
Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia
This study will compare the safety and effectiveness of three different antipsychotic medications, as well as the use of other medications to limit treatment side effects, in adults with schizophrenia.
- Trial name
- COATS (NCT00802100)
- Testing
- Olanzapine, Perphenazine, Aripiprazole
- Where
- 13 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)
This study is a sequential multiple-assignment randomized trial (RCT) of antipsychotic medication treatment in first-episode schizophrenia patients in the real-world settings.Through analysis of treatment efficacy rate and…
- Trial name
- NCT03510325
- Testing
- Phase 1: Olanzapine, Phase 1: Risperidone, Phase 1: Amisulpride
- Where
- 7 sites in China
- Volunteers
- 762 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics
This is a randomized, double-blind, placebo-controlled, sequential cohort, ascending oral dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of EVP-6308 administered for 14 days in subjects with…
- Trial name
- NCT02037074
- Testing
- Drug: EVP-6308
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia
Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone
The primary purpose of this study is to determine whether a combination of ACP-103 (the study medication) with either haloperidol or risperidone will show antipsychotic efficacy and that it is safe and well tolerated.
- Trial name
- NCT00361166
- Testing
- ACP-103
- Where
- 17 sites in United States, Brazil
- Volunteers
- 400 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia
Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia
AVE1625 is a new potent and selective cannabinoid 1 (CB1) antagonist in clinical development for the treatment of cognitive impairment in patients diagnosed with schizophrenia.
- Trial name
- CONNECT (NCT00439634)
- Testing
- AVE1625
- Where
- 2 sites in United States, Canada
- Volunteers
- 873 people
- Sponsor
- Sanofi
Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology
Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach
The objective of this study is to respond to frequent requests from patients who wish to reduce or even stop their antipsychotic treatment once they have achieved clinical stability.
- Conditions
- Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- DREAMS-Phen (NCT07152184)
- Testing
- Use of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate / Pipotiazine - Quetiapine - Flup
- Volunteers
- 288 people
- Sponsor
- University Hospital, Strasbourg, France